✨ Policy Statement and Medicines Consent
NEW ZEALAND GAZETTE, No. 64
12 MAY 2011
1486
POLICY D1
Local authorities shall take reasonable steps to:
(a) involve iwi and hapū in the management of fresh water and freshwater ecosystems in the region;
(b) work with iwi and hapū to identify tangata whenua values and interests in fresh water and freshwater ecosystems in the region; and
(c) reflect tangata whenua values and interests in the management of, and decision-making regarding, fresh water and freshwater ecosystems in the region.
E. PROGRESSIVE IMPLEMENTATION PROGRAMME
POLICY E1
(a) This policy applies to the implementation by a regional council of a policy of this national policy statement.
(b) Every regional council is to implement the policy as promptly as is reasonable in the circumstances, and so it is fully completed by no later than 31 December 2030.
(c) Where a regional council is satisfied that it is impracticable for it to complete implementation of a policy fully by 31 December 2014, the council may implement it by a programme of defined time-limited stages by which it is to be fully implemented by 31 December 2030.
(d) Any programme of time-limited stages is to be formally adopted by the council within 18 months of the date of gazetting of this national policy statement, and publicly notified.
(e) Where a regional council has adopted a programme of staged implementation, it is to publicly report, in every year, on the extent to which the programme has been implemented.
REBECCA KITTERIDGE, Clerk of the Executive Council.
go3045
Health
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: DBL Rocuronium Bromide Injection
Active Ingredient: Rocuronium bromide 50mg
Dosage Form: Solution for injection
New Zealand Sponsor: Hospira NZ Limited
Manufacturer: Hospira Inc, North Carolina, United States of America
Product: Full Marks Solution
Active Ingredient: Isopropyl myristate 50%w/w
Dosage Form: Solution
New Zealand Sponsor: SSL New Zealand Limited
Manufacturer: SSL International Plc, County Durham, United Kingdom
Product: Kuvan
Active Ingredient: Sapropterin dihydrochloride 100mg equivalent to sapropterin 77mg
Dosage Form: Soluble tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturers: Excella GmbH, Feucht, Germany, Lyne Laboratories Inc, Massachusetts, United States of America
Product: ParaCode
Active Ingredients: Codeine phosphate hemihydrate 8mg equivalent to codeine 5.92mg
Paracetamol 500mg
Dosage Form: Tablet
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: Rusan Pharma Limited, Gujarat, India
Product: Privigen
Active Ingredient: Normal immunoglobulin 10%
Dosage Form: Solution for infusion
New Zealand Sponsor: CSL Biotherapies (NZ) Limited
Manufacturers: CSL Behring LLC, Illinois, United States of America, CSL Behring AG, Bern, Switzerland
Next Page →
NZ Gazette 2011, No 64
✨ LLM interpretation of page content
National Policy Statement for Freshwater Management 2011
(continued from previous page)
EnvironmentResource Management Act 1991, Freshwater Management, National Policy Statement, Treaty of Waitangi, Water Quality, Water Quantity, Allocation, Environmental Flows, Limits, Monitoring, Review
- REBECCA KITTERIDGE, Clerk of the Executive Council
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social WelfareMedicines Act 1981, New Medicines, Distribution Consent, Healthcare Products
- Minister of Health